Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2020, COVID
2020

The nature of eculizumab monoclonal antibody and its potential against coronavirus infection COVID-19: 616.92/93-035.1-085

COVID
Published 2020-06-22
Dmitry A. Kudlay
GENERIUM JSC; 10 Testovskaya Str., Moscow 123112, Russia; National Research Center — Institute of Immunology, Federal Medical-Biological Agency of Russia; 24 Kashirskoe Highway, Moscow 115478, Russia;
АО «ГЕНЕРИУМ»; Россия, 123112 Москва, ул. Тестовская, 10; ФГБУ «Государственный научный центр “Институт иммунологии” Федерального медико-биологического агентства»; Россия, 115478 Москва, Каширское шоссе, 24;
https://orcid.org/0000-0003-1878-4467 (unauthenticated)
Bulat A. Bakirov
Bashkir State Medical University, Health Ministry of Russian Federation; 3 Lenin Str., Ufa 450008, Russia
ФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 450008 Уфа, ул. Ленина, 3
http://orcid.org/0000-0002-3297-1608 (unauthenticated)
Valentin N. Pavlov
Bashkir State Medical University, Health Ministry of Russian Federation; 3 Lenin Str., Ufa 450008, Russia
ФГБОУ ВО «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 450008 Уфа, ул. Ленина, 3
http://orcid.org/0000-0003-2125-4897 (unauthenticated)

Keywords

new coronavirus infection
COVID-19
SARS-CoV-2
complement system
eculizumab
  Full Text

Abstract

vAt present, the continuing spread of a new coronavirus infection, COVID-19, remains a serious problem in the world. The World Health Organization announced the COVID-19 pandemic on 11.03.2020. The causative agent of the disease is SARS-CoV-2, a single-stranded (+) RNA virus from the genus of beta-coronaviruses. Activation of the complement system, including the C5a component, is involved in the development of acute inflammatory process in the lungs caused by pathogenic viruses. Preclinical studies have revealed the fact of excessive activation of the complement system in coronavirus infection. Eculizumab completely inhibits the C5-mediated activity of the terminal complement complex that suggests its effectiveness in the treatment of lung damage, severe pneumonia, and acute respiratory distress syndrome in COVID-19 patients. Clinical cases of eculizumab effective use in patients with COVID-19, starting from the first days of treatment, are presented. Currently, clinical studies of the efficacy and safety of eculizumab, as well as similar complement-blocking drug in the treatment of patients with a new coronavirus infection have been approved.

REFERENCES

  1. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140–6736(20)30183–5.
  2. Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. DOI: 10.1016/ S0140–6736(20)30251–8.
  3. ZhuN.,ZhangD.,WangW.etal.Anovelcoronavirusfrompatients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727– 33. DOI: 10.1056/NEJMoa2001017.
  4. Chan J.F., Yuan S., Kok K.H. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–52. DOI: 10.1016/S0140–6736(20)30154–9.
  5. LiQ.,GuanX.,WuP.etal.EarlytransmissiondynamicsinWuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207. DOI: 10.1056/NEJMoa2001316.
  6. Phan L.T., Nguyen T.V., Luong Q.C. et al. Importation and humanto-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020;382(9):872–4. DOI: 10.1056/NEJMc2001272.
  7. RotheC.,SchunkM.,SothmannP.etal.Transmissionof2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–1. DOI: 10.1056/NEJMc2001468.
  8. Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395(10225):689–97. DOI: 10.1016/S0140–6736(20)30260–9.
  9. Coronavirus disease (COVID-19) outbreak situation. World Health Organization. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed: 30.05.2020].
  10. Holshue M.L., DeBolt C., Lindquist S. et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929– 36. DOI: 10.1056/NEJMoa2001191.
  11. NationalHealthCommissionofthePeople’sRepublicofChina.Home page. Available at: http://www.nhc.gov.cn. [Accessed: 30.05.2020].
  12. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/coronavirus/2019-ncov/summary.html. [Accessed: 30.05.2020].
  13. Hammerschmidt D.E., Hudson L.D., Weaver L.J. et al. Association of complement activation and elevated plasma-c5a with adult respiratory distress syndrome: pathophysiological relevance and possible prognostic value. Lancet. 1980;315(8175):947–9. DOI: 10.1016/S0140–6736(80)91403–8.
  14. GralinskiL.E.,SheahanT.P.,MorrisonT.E.etal.Complementactivation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5). pii: e01753–18. DOI: 10.1128/ mBio. 01753–18.
  15. Wang R., Xiao H., Guo R. et al. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015;4(5):e28. DOI: 10.1038/emi.2015.28.
  16. Jiang Y., Zhao G., Song N. et al. Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):77. DOI: 10.1038/ s41426-018-0063-8.
  17. Kudlay D.A. Immunometabolic aspects of the pathogenesis of polytrauma. [Immunometabolicheskie aspekty patogeneza politravmy]. Avtoref. dis. dokt. med. nauk. Novosibirsk, 2007. 42 s. (In Russ.).
  18. Ceccarelli M., Berretta M., Venanzi Rullo E. et al. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur Rev Med Pharmacol Sci. 2020;24(5):2781– 3. DOI: 10.26355/eurrev_202003_20551.
  19. Niazi S.K. Biosimilars and interchangeable biologics: strategic elements. CRC Press, 2018. 645 p. DOI: 10.1201/b19161.
  20. Dmytrijuk A., Robie-Suh K., Cohen M. et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist. 2008;13(9):993–1000. DOI: 10.1634/theoncologist.2008–0086.

  21. Jodele S., Medvedovic M., Luebbering N. et al. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166–77. DOI: 10.1182/bloodadvances.2020001515.

  22. Nunius C., Büttner-Herold M., Bertz S. et al. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome — a case report. BMC Nephrol. 2020;21(1):104. DOI: 10.1186/s12882-020-01766-0.

  23. Olson S.R., Lu E., Sulpizio E. et al. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48(2):96–107. DOI: 10.1159/000492033.

  24. Roselli F., Karasu E., Volpe C., Huber-Lang M. Medusa’s head: the complement system in traumatic brain and spinal cord injury. J Neurotrauma. 2018;35(2):226–40. DOI: 10.1089/neu.2017.5168.

  25. Wong C.K., Lam C.W.K., Wu A.K.L. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. DOI: 10.1111/j.1365–2249.2004.02415.x.

  26. Ivanov R., Sekaryova G., Kravtsova O. et al. Guidelines of research biosimilar drugs. [Pravila provedeniya issledovanij bioanalogovyh lekarstvennyh sredstv (bioanalogov)]. Farmakokinetika i farmakodinamika. 2014;(1):21–36. (In Russ.).

  27. Rules for conducting research on biological drugs of the Eurasian Economic Union. Approved by the decision of the Council of the Eurasian Economic Commission No89 from 03.11.2016. [Pravila provedeniya issledovanij biologicheskih lekarstvennyh sredstv Evrazijskogo ekonomicheskogo soyuza. Utverzhdeny resheniem Soveta Evrazijskoj ekonomicheskoj komissii No89 ot 3.11.2016]. 714 s. (In Russ.). Available at: http://docs.cntd.ru/document/456026116. [Accessed: 30.05.2020].

  28. Simonov V.M., Pantushenko M.S., Kazarov A.A. et al. Development and validation of a method for determination of Eculizumab concentration in human plasma by biolayer interferometry. [Razrabotka i validaciya metodiki opredeleniya koncentracii ekulizumaba v plazme krovi cheloveka s primeneniem tekhnologii bioslojnoj interferometrii]. BIOpreparaty. Profilaktika, diagnostika, lechenie. 2017;17(3):158–64. (In Russ.).

  29. Kulagin A., Ptushkin V., Lukina E. et al. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood. 2019;134(Suppl 1):3748. DOI: 10.1182/blood-2019–125693.

  30. Emirova K.M., Orlova O.M., Muzurov A.L. et al. The experience of using Elizaria® for atypical hemolytic uremic syndrome. [Opyt primeneniya Elizarii® pri atipichnom gemolitiko-uremicheskom syndrome]. Pediatriya. Zhurnal im. G.N. Speranskogo. 2019;98(5):225–9. (In Russ.). DOI: 10.24110/0031-403X-2019-98-5-225-229.
  31. Lavrishcheva I.V., Jakovenko A.A., Kudlay D.A. A case report of atypical hemolytic-uremic syndrome treatment with the first Russian eculizumab in adult patient. Urol Nephrol Open Access J. 2020;8(2):37–40.
  32. Perrella A., Carannante N., Berretta M. et al. Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches? Eur Rev Med Pharmacol Sci. 2020;24:2162–4. DOI: 10.26355/eurrev_202002_20396.
  33. Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Istituto Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale: 30 marzo 2020. 12 p. Available at: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettinosorveglianza-integrata-COVID-19_30-marzo-2020.pdf. [Accessed: 30.05.2020].
  34. Iba T., Levi M., Levy J.H. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost. 2020;46(1):89–95. DOI: 10.1055/s-0039–1694995.
  35. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. DOI: 10.1111/jth.14768.
  36. GuanW.J., NiZ.Y., HuY. et al; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. DOI: 10.1056/NEJMoa2002032. [Epub ahead of print].
  37. Li Y., Wang M., Yifan Zhou Y. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN (Preprint). DOI: 10.2139/ssrn.3550025.
  38. OxleyT.J., Mocco J., Majidi et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med. 2020 Apr 28. DOI: 10.1056/NEJMc2009787. [Epub ahead of print].
  39. Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–44. DOI: 10.1160/TH16-08-0620.